Biotech stocks for your portfolio: Synta Pharmaceu
Post# of 23071
Posted On: 04/26/2016 9:08:36 AM
Biotech stocks for your portfolio: Synta Pharmaceuticals (SNTA), Intrexon (XON)
Advertisement
Synta Pharmaceuticals Corp. (SNTA) ended last trading session with a change of 6.89 percent. It trades at an average volume of 1.33M shares versus 2.12M shares recorded at the end of last trading session. The share price of $0.40 is at a distance of 163.67 percent from its 52-week low and down -86.9 percent versus its peak. The company has a market cap of $51.20M and currently has 129.46M shares outstanding. The share price is currently 40.25 percent versus its SMA20, 55.22 percent versus its SMA50, and -58.46 percent versus its SMA200. The stock has a weekly performance of 13 percent and is 13 percent year-to-date as of the recent close.
Synta Pharmaceuticals Corp. (SNTA) and Madrigal Pharmaceuticals, Inc., a privately-held company (“Madrigal”), announced on April 14, 2016, that they have entered into a definitive merger agreement (the “Merger”) under which Madrigal will merge with a wholly-owned subsidiary of Synta in an all-stock transaction. The Merger will create a company focused on the development of novel small-molecule drugs addressing major unmet needs in cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). Madrigal’s lead compound, MGL-3196, is a Phase 2-ready once-daily, oral, liver-directed selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of NASH and heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH). Upon closing of the transaction, the combined company will be named Madrigal Pharmaceuticals, and Paul A. Friedman, M.D. will become Chairman and Chief Executive Officer.
Under the terms of the merger agreement, Synta will acquire all outstanding shares of Madrigal in exchange for approximately 253.9 million newly issued shares of Synta common stock. Upon completion of the proposed acquisition, it is anticipated that existing Synta shareholders will own 36.0% of the combined company and Madrigal shareholders will own 64.0% of the combined company. The transaction has been approved by the boards of directors of both companies and the shareholders of Madrigal. The merger is expected to close by the end of the third quarter of 2016, subject to customary closing conditions, including approval of the merger by the shareholders of Synta.
See Also: Breaking: A Peek Inside Donald Trump’s Financials Shows How He Takes Advantage Of A Little Known Income Stream That’s Available To Everyone!
Intrexon Corporation (XON) recently recorded -4.14 percent change and currently at $27.81 is 50.16 percent away from its 52-week low and down -59.96 percent versus its peak. It has a past 5-day performance of -24.82 percent and trades at an average volume of 2.16M shares. The stock has a 1-month performance of -22.62 percent and is -7.76 percent year-to-date as of the recent close. There were about 116.53M shares outstanding which made its market cap $3.24B. The share price is currently -19.18 percent versus its SMA20, -19.4 percent versus its SMA50, and -26.67 percent versus its SMA200.
Intrexon Corporation (XON) on April 22, 2016 provided an update to its shareholders regarding recent trading activity in the company’s common stock. On Thursday, April 21, 2016, a materially false and misleading report regarding the company, its subsidiaries and its chairman and CEO was published on Seeking Alpha, a financial blog.
On April 21, 2016 , Intrexon received a draft report, dated December 2015, which contained similarly inaccurate claims and strikingly similar language, in some parts identical words, to that used in yesterday’s report. Moreover, Intrexon received information that the source of the report was a particular hedge fund seeking to discredit Intrexon. The hedge fund, according to our information, desired to take a short position in the company’s stock, was seeking a willing publisher of its report on the company, and intended to benefit from trading activity caused thereby.
Based on this information, Intrexon believes that it is the target of a campaign to manipulate trading in the company’s securities, interfere with the company’s business operations, and destroy the reputation of the company and its chairman and CEO. Intrexon, with the advice of counsel, is taking appropriate steps in light of these developments. In the meantime, we wish to assure our investors, collaboration partners, and employees that the company remains dedicated to advancing our business and t
Advertisement
Synta Pharmaceuticals Corp. (SNTA) ended last trading session with a change of 6.89 percent. It trades at an average volume of 1.33M shares versus 2.12M shares recorded at the end of last trading session. The share price of $0.40 is at a distance of 163.67 percent from its 52-week low and down -86.9 percent versus its peak. The company has a market cap of $51.20M and currently has 129.46M shares outstanding. The share price is currently 40.25 percent versus its SMA20, 55.22 percent versus its SMA50, and -58.46 percent versus its SMA200. The stock has a weekly performance of 13 percent and is 13 percent year-to-date as of the recent close.
Synta Pharmaceuticals Corp. (SNTA) and Madrigal Pharmaceuticals, Inc., a privately-held company (“Madrigal”), announced on April 14, 2016, that they have entered into a definitive merger agreement (the “Merger”) under which Madrigal will merge with a wholly-owned subsidiary of Synta in an all-stock transaction. The Merger will create a company focused on the development of novel small-molecule drugs addressing major unmet needs in cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). Madrigal’s lead compound, MGL-3196, is a Phase 2-ready once-daily, oral, liver-directed selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of NASH and heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH). Upon closing of the transaction, the combined company will be named Madrigal Pharmaceuticals, and Paul A. Friedman, M.D. will become Chairman and Chief Executive Officer.
Under the terms of the merger agreement, Synta will acquire all outstanding shares of Madrigal in exchange for approximately 253.9 million newly issued shares of Synta common stock. Upon completion of the proposed acquisition, it is anticipated that existing Synta shareholders will own 36.0% of the combined company and Madrigal shareholders will own 64.0% of the combined company. The transaction has been approved by the boards of directors of both companies and the shareholders of Madrigal. The merger is expected to close by the end of the third quarter of 2016, subject to customary closing conditions, including approval of the merger by the shareholders of Synta.
See Also: Breaking: A Peek Inside Donald Trump’s Financials Shows How He Takes Advantage Of A Little Known Income Stream That’s Available To Everyone!
Intrexon Corporation (XON) recently recorded -4.14 percent change and currently at $27.81 is 50.16 percent away from its 52-week low and down -59.96 percent versus its peak. It has a past 5-day performance of -24.82 percent and trades at an average volume of 2.16M shares. The stock has a 1-month performance of -22.62 percent and is -7.76 percent year-to-date as of the recent close. There were about 116.53M shares outstanding which made its market cap $3.24B. The share price is currently -19.18 percent versus its SMA20, -19.4 percent versus its SMA50, and -26.67 percent versus its SMA200.
Intrexon Corporation (XON) on April 22, 2016 provided an update to its shareholders regarding recent trading activity in the company’s common stock. On Thursday, April 21, 2016, a materially false and misleading report regarding the company, its subsidiaries and its chairman and CEO was published on Seeking Alpha, a financial blog.
On April 21, 2016 , Intrexon received a draft report, dated December 2015, which contained similarly inaccurate claims and strikingly similar language, in some parts identical words, to that used in yesterday’s report. Moreover, Intrexon received information that the source of the report was a particular hedge fund seeking to discredit Intrexon. The hedge fund, according to our information, desired to take a short position in the company’s stock, was seeking a willing publisher of its report on the company, and intended to benefit from trading activity caused thereby.
Based on this information, Intrexon believes that it is the target of a campaign to manipulate trading in the company’s securities, interfere with the company’s business operations, and destroy the reputation of the company and its chairman and CEO. Intrexon, with the advice of counsel, is taking appropriate steps in light of these developments. In the meantime, we wish to assure our investors, collaboration partners, and employees that the company remains dedicated to advancing our business and t
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'